Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Phase 1 Terminated
34 enrolled
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled 43 charts
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Phase 1 Terminated
10 enrolled
A Study of PHN-010 in Patients With Advanced Solid Tumors
Phase 1 Terminated
26 enrolled
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Phase 1 Terminated
250 enrolled
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Phase 1 Terminated
18 enrolled 19 charts
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Phase 1 Terminated
78 enrolled
(VELA) Study of BLU-222 in Advanced Solid Tumors
Phase 1 Terminated
50 enrolled
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Phase 1 Terminated
17 enrolled
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
82 enrolled
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Phase 1 Terminated
25 enrolled
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
23 enrolled
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
Phase 1 Terminated
58 enrolled
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Phase 1 Terminated
9 enrolled
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Phase 1 Terminated
1 enrolled 5 charts
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
Phase 1 Terminated
4 enrolled
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
11 enrolled
AM-003
Phase 1 Terminated
5 enrolled
A Study to Investigate LYL797 in Adults With Solid Tumors
Phase 1 Terminated
57 enrolled
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
Phase 1 Terminated
221 enrolled
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Phase 1 Terminated
16 enrolled
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Phase 1 Terminated
85 enrolled
C4431001
Phase 1 Terminated
30 enrolled 20 charts
MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1 Terminated
46 enrolled 13 charts
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Phase 1 Terminated
133 enrolled
A Study of SGN-ALPV in Advanced Solid Tumors
Phase 1 Terminated
43 enrolled
A Study of SGN-STNV in Advanced Solid Tumors
Phase 1 Terminated
111 enrolled
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Phase 1 Terminated
127 enrolled
Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1 Terminated
4 enrolled
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
37 enrolled 32 charts
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
Phase 1 Terminated
3 enrolled
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
78 enrolled 39 charts
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
Phase 1 Terminated
53 enrolled
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Phase 1 Terminated
22 enrolled
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Phase 1 Terminated
13 enrolled 16 charts
A Study of PY314 in Subjects With Advanced Solid Tumors
Phase 1 Terminated
86 enrolled
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Phase 1 Terminated
24 enrolled
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b
Phase 1 Terminated
31 enrolled
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer
Phase 1 Terminated
56 enrolled
Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
Phase 1 Terminated
27 enrolled
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Phase 1 Terminated
16 enrolled
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Phase 1 Terminated
87 enrolled
ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
Phase 1 Terminated
14 enrolled
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
Phase 1 Terminated
34 enrolled
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
BRCA
Phase 1 Terminated
1 enrolled
BrUOG 390: Neoadjuvant Treatment With Talazoparib
Phase 1 Terminated
1 enrolled 10 charts
Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer
Phase 1 Terminated
1 enrolled 4 charts
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1 Terminated
5 enrolled